Buchanan, Fritz G.

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Lasko, L. M., Jakob, C. G., Edalji, R. P., Qiu, W., Montgomery, D., Digiammarino, E. L., Hansen, T. M., Risi, R. M., Frey, R., Manaves, V., et al. (2017) · Nature

Histone Deacetylase Inhibitors ResearchProtein Degradation and Inhibitors

Cited by 858

The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex

He, Y., Selvaraju, S., Curtin, M. L., Jakob, C. G., Zhu, H., Comess, K. M., Shaw, B., The, J., Lima-Fernandes, E., Szewczyk, M. M., et al. (2017) · Nature Chemical Biology

Epigenetics and DNA MethylationCancer-related gene regulation

Cited by 224

Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate

Singh, S., Serwer, L., DuPage, A., Elkins, K., Chauhan, N., Ravn, M., Buchanan, F., Wang, L., Krimm, M., Wong, K., et al. (2022) · Molecular Cancer Therapeutics

Monoclonal and Polyclonal Antibodies ResearchToxin Mechanisms and Immunotoxins

Cited by 41